When a vaccine designed to protect girls against a sexually transmitted virus arrived three years ago, the debate centered on one question: Would the shots make young girls more likely to have sex?
Now the vaccine’s maker is trying to get approval to sell the vaccine for boys, and the debate is focusing on something else entirely: Is it worth the money, and is it safe and effective enough?
“We are still more worried about the promiscuity of girls than the promiscuity of boys,” said Susan M. Reverby, a professor of women’s studies and medical history at Wellesley College. “There’s still that double standard.”
